Voiant, a Waltham, MA-based clinical trial imaging solutions provider, acquired Voxeleron, an Austin, TX-based company which specializes AI-driven ophthalmic image analysis.
The amount of the deal was not disclosed.
With the acquisition, Volant will accelerate the development of innovative treatments for eye diseases.
Voxeleron is an AI-driven ophthalmic image analysis company offering advanced solutions for applications in medicine, biology, and beyond. Its platform provides image analysis software for all ophthalmic imagery, enabling researchers to accelerate clinical research, generate actionable results, and drive better patient outcomes.
Led by CEO Jim Primerano, Voiant is an AI-based clinical trial imaging solution provider with scientific and clinical domain expertise, offering biopharmaceutical companies with high-speed delivery of quality clinical endpoint data.
The company will leverage its newly combined capabilities with continued investment to advance biomarker development and image analysis capabilitie
